Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
115,037,875
-
Share change
-
+2,160,020
-
Total reported value
-
$2,465,293,115
-
Put/Call ratio
-
82%
-
Price per share
-
$21.46
-
Number of holders
-
208
-
Value change
-
+$48,272,802
-
Number of buys
-
99
-
Number of sells
-
88
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2023
As of 31 Dec 2023,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
208 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,037,875 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Temasek Holdings (Private) Ltd, Crestline Management, LP, STATE STREET CORP, TAKEDA PHARMACEUTICAL CO LTD, Capital Research Global Investors, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
208
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.